A chilled focus on global expansion for Love Hemp Group
“…we have had a lot of Institutional interest and with wanting to move now to the Main Market we can now supply that demand…”
There’s been a flurry of cannabis-related investment activity with fundraises and industry listings, and Love Hemp Group‘s chief executive Tony Calamita supports his peers and wishes them ‘all the best’ because he doesn’t see them as either meaningful or mindful competition.
“The main difference with Love Hemp is we are a CBD business with heritage, we have significantly growing revenue year on year, we have a strong consumer database as well as presence in national retail and I believe we have the most exciting growth plans on a global scale.”
He thanks the other businesses for adding to the attention the cannabinoid space is receiving, and perhaps that’s one of the reasons Love Hemp managed to raise an extra £2 million bringing the entire raise to just over £7 million.
The money is earmarked for global expansion with a move to the USA in a matter of weeks and a move from the Aquis exchange to the Main Market of the London Stock Exchange during the course of this year.
Calamita is grateful for the time the company has spent on Aquis, but reckons now while there’s momentum in the sector, his peers and more importantly confidence in his company Love Hemp is ripe for an uplist.
It’s also the product range and those who stock #LIFE’s goods that are imbuing the market with confidence.
Calamita is one of the few bosses who uses the products he sells. He’s a 21st century equivalent of Victor Kermit Kiam II who liked the shaver so much he bought the company.
Calamita has a busy mind and to quiet, but not dull it, he uses Love Hemp therapies that give him a ‘chilled focus’ and as he shares with Sarah Lowther it’s vital he gets some quality sleep as the next few months will be equally busy.
Watch Tony tell Proactive London’s Katie Pilbeam about Love Hemp’s post-fundraise strategy.
Click here to access #LIFE’s latest corporate presentation
The author was remunerated but does not hold shares in the company
